Biomapas Buys Alira Health's CMC Business
The deal adds a specialist chemistry, manufacturing, and controls line to Biomapas' services as it enters the U.S. market.
Updated on Nov. 16, 2026 in Healthcare

Biomapas has acquired the chemistry, manufacturing, and controls (CMC) business of Alira Health and established Biomapas North America as its new U.S. business. The Alira Health team, based in Boston, provides integrated CMC solutions to preclinical- and clinical-stage biopharmaceutical companies.
Why it matters
The move gives Biomapas a physical presence in the United States, its clients' largest market, which the company considers crucial to its strategy. Alira Health clients will continue to work with the same team and contacts after the acquisition.
The Alira Health CMC team has more than 35 members and has helped nearly 100 clients in the U.S. and Europe move products from clinical development to market. The deal's price and how many staff will transfer were not disclosed.
The players
Biomapas
Biomapas is a life sciences services company that offers regulatory affairs, pharmacovigilance, product and clinical development, and digital and consulting services to biopharmaceutical companies.
Alira Health
Alira Health is a healthcare consulting firm whose Boston-based team provides integrated CMC solutions to biopharmaceutical developers in the U.S. and Europe.
The details
The Alira Health team offers outsourced clinical manufacturing, quality assurance oversight, CMC regulatory strategy and filings, and project management, with experience in complex biologics, small molecules, and peptides. The business adds a specialist CMC line to Biomapas' existing regulatory affairs, pharmacovigilance, product and clinical development, and digital and consulting services.
Timeline
November 16, 2026: Biomapas announced its entry into the U.S. market with the acquisition and the establishment of Biomapas North America.
Market Landscape
The deal reflects biopharmaceutical service providers expanding their CMC offerings to follow clients into the United States, which Biomapas identifies as its clients' largest market. It positions Biomapas to compete for U.S.-based drug developers that need integrated manufacturing and regulatory support from preclinical through commercial stages.
Existing Alira Health clients will keep working with the same team and contacts, so their day-to-day relationships are not expected to change. Biomapas' expansion into the U.S. may give biopharmaceutical developers in the region a closer option for integrated CMC and regulatory support.
The takeaway
Companies developing biologics, small molecules, or peptides can look for integrated CMC and regulatory partners that cover the full path from clinical development to market. Local presence in the U.S. market is becoming a practical consideration when choosing a service provider.
Further reading
For more on the regional industry, explore Healthcare coverage from Boston.
Source note: This article includes information reported by Contract Pharma.










